S212: A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF JAKTINIB VERSUS HYDROXYUREA IN PATIENTS WITH INTERMEDIATE-2 OR HIGH RISK MYELOFIBROSIS
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000967760.70775.53 |
| _version_ | 1797280158116216832 |
|---|---|
| author | Yi Zhang Hu Zhou Junling Zhuang Aili He Yarong LI Linhua Yang Xin Du Sujun Gao Guangsheng He Mei Hong Qian Jiang Zhongxing Jiang Sun Kai Lingling Yue Cuiping Zheng Zeping Zhou Chenghao Jin Hongmei Jing Lin Liu Qingchi Liu Jishi Wang Wen Wu Yajing Xu Dengshu Wu Na Xu Feng Zhang Jin Zhang Huanling Zhu Zhijian Xiao Jie Jin |
| author_facet | Yi Zhang Hu Zhou Junling Zhuang Aili He Yarong LI Linhua Yang Xin Du Sujun Gao Guangsheng He Mei Hong Qian Jiang Zhongxing Jiang Sun Kai Lingling Yue Cuiping Zheng Zeping Zhou Chenghao Jin Hongmei Jing Lin Liu Qingchi Liu Jishi Wang Wen Wu Yajing Xu Dengshu Wu Na Xu Feng Zhang Jin Zhang Huanling Zhu Zhijian Xiao Jie Jin |
| author_sort | Yi Zhang |
| collection | DOAJ |
| first_indexed | 2024-03-07T16:37:14Z |
| format | Article |
| id | doaj.art-3a3f14cafc374031a2e0311abb074503 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T16:37:14Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-3a3f14cafc374031a2e0311abb0745032024-03-03T09:43:09ZengWileyHemaSphere2572-92412023-08-017e707755310.1097/01.HS9.0000967760.70775.53202308003-00114S212: A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF JAKTINIB VERSUS HYDROXYUREA IN PATIENTS WITH INTERMEDIATE-2 OR HIGH RISK MYELOFIBROSISYi Zhang0Hu Zhou1Junling Zhuang2Aili He3Yarong LI4Linhua Yang5Xin Du6Sujun Gao7Guangsheng He8Mei Hong9Qian Jiang10Zhongxing Jiang11Sun Kai12Lingling Yue13Cuiping Zheng14Zeping Zhou15Chenghao Jin16Hongmei Jing17Lin Liu18Qingchi Liu19Jishi Wang20Wen Wu21Yajing Xu22Dengshu Wu23Na Xu24Feng Zhang25Jin Zhang26Huanling Zhu27Zhijian Xiao28Jie Jin291 The First Affiliated Hospital, Zhejiang University School of Medicine, Department of Hematology, Hangzhou, China2 The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Department of Hematology, Zhengzhou, China3 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Department of Hematology, Beijing, China4 The Second Affiliated Hospital of Xi’an Jiaotong University, Department of Hematology, Xi’an, China5 The Second Hospital of Jilin University, Department of Hematology and Oncology, Changchun, China6 The Second Affiliated Hospital of Shanxi Medical University, Department of Hematology, Taiyuan, China7 Guangdong Provincial People’s Hospital, Department of Hematology, Guangzhou, China8 The First Hospital of Jilin University, Department of Hematology, Changchun, China9 The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Key Laboratory of Hematology of Nanjing Medical University, Collaborative Innovation Center for Cancer Personalize, Department of Hematology, Nanjing, China10 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Department of Hematology, Wuhan, China11 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China12 The First Affiliated Hospital of Zhengzhou University, Department of Hematology, Zhengzhou, China13 Henan Provincial People’s Hospital, Department of Hematology, Zhengzhou, China14 Lanzhou University Second Hospital, Department of Hematology and Oncology, Lanzhou, China15 Wenzhou Central Hospital, Second Department of Oncology, Wenzhou, China16 The Second Affiliated Hospital of Kunming Medical University, Department of Hematology, Kunming, China17 Jiangxi Provincial People’s Hospital, Department of Hematology, Nanchang, China18 Peking University Third Hospital, Department of Hematology, Beijing, China19 The First Affiliated Hospital of Chongqing Medical University, Department of Hematology, Chongqing, China20 The First Hospital of Hebei Medical University, Department of Hematology, Shijiazhuang, China21 Affiliated Hospital of Guizhou Medical University, Department of Hematology, Guiyang, China22 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Department of Hematology, Shanghai, China23 Xiangya hospital, Central South University, Department of Hematology, Changsha, China23 Xiangya hospital, Central South University, Department of Hematology, Changsha, China24 Nanfang Hospital, Southern Medical University, Department of Hematology, Guangzhou, China25 The First Affiliated Hospital of Bengbu Medical College, Department of Hematology, Bengbu, China26 Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Department of Hematology, Hangzhou, China27 West China Hospital, Sichuan University, Department of Hematology, Chengdu, China28 Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China1 The First Affiliated Hospital, Zhejiang University School of Medicine, Department of Hematology, Hangzhou, Chinahttp://journals.lww.com/10.1097/01.HS9.0000967760.70775.53 |
| spellingShingle | Yi Zhang Hu Zhou Junling Zhuang Aili He Yarong LI Linhua Yang Xin Du Sujun Gao Guangsheng He Mei Hong Qian Jiang Zhongxing Jiang Sun Kai Lingling Yue Cuiping Zheng Zeping Zhou Chenghao Jin Hongmei Jing Lin Liu Qingchi Liu Jishi Wang Wen Wu Yajing Xu Dengshu Wu Na Xu Feng Zhang Jin Zhang Huanling Zhu Zhijian Xiao Jie Jin S212: A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF JAKTINIB VERSUS HYDROXYUREA IN PATIENTS WITH INTERMEDIATE-2 OR HIGH RISK MYELOFIBROSIS HemaSphere |
| title | S212: A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF JAKTINIB VERSUS HYDROXYUREA IN PATIENTS WITH INTERMEDIATE-2 OR HIGH RISK MYELOFIBROSIS |
| title_full | S212: A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF JAKTINIB VERSUS HYDROXYUREA IN PATIENTS WITH INTERMEDIATE-2 OR HIGH RISK MYELOFIBROSIS |
| title_fullStr | S212: A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF JAKTINIB VERSUS HYDROXYUREA IN PATIENTS WITH INTERMEDIATE-2 OR HIGH RISK MYELOFIBROSIS |
| title_full_unstemmed | S212: A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF JAKTINIB VERSUS HYDROXYUREA IN PATIENTS WITH INTERMEDIATE-2 OR HIGH RISK MYELOFIBROSIS |
| title_short | S212: A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF JAKTINIB VERSUS HYDROXYUREA IN PATIENTS WITH INTERMEDIATE-2 OR HIGH RISK MYELOFIBROSIS |
| title_sort | s212 a randomized double blind phase 3 study of jaktinib versus hydroxyurea in patients with intermediate 2 or high risk myelofibrosis |
| url | http://journals.lww.com/10.1097/01.HS9.0000967760.70775.53 |
| work_keys_str_mv | AT yizhang s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT huzhou s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT junlingzhuang s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT ailihe s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT yarongli s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT linhuayang s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT xindu s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT sujungao s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT guangshenghe s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT meihong s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT qianjiang s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT zhongxingjiang s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT sunkai s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT linglingyue s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT cuipingzheng s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT zepingzhou s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT chenghaojin s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT hongmeijing s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT linliu s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT qingchiliu s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT jishiwang s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT wenwu s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT yajingxu s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT dengshuwu s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT naxu s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT fengzhang s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT jinzhang s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT huanlingzhu s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT zhijianxiao s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis AT jiejin s212arandomizeddoubleblindphase3studyofjaktinibversushydroxyureainpatientswithintermediate2orhighriskmyelofibrosis |